Stockholders' Equity	9 Months Ended
Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity Description of Capital Stock The Company has authorized share capital consisting of 750 million shares of common stock, par value $0.01 per share, and 1 million shares of preferred stock, par value $0.01 per share. Each share of common stock is equal in all respects to every other share of common stock of the Company. Each share of common stock is entitled to one vote per share at each annual or special meeting of stockholders for the election of directors and upon any other matter coming before such meeting. Subject to all the rights of the preferred stock, dividends may be paid to holders of common stock as and when declared by the Board of Directors. Cash Dividends During the nine months ended December 31, 2018, the Board of Directors declared cash dividends to our stockholders of approximately $25 million in the aggregate, of which $17 million had been paid as of December 31, 2018 and $8 million of which was paid on January 15, 2019. On February 13, 2019, the Board of Directors declared a dividend of $0.05 per share payable on April 16, 2019 to common stockholders of record at the close of business on March 27, 2019. Share Repurchase Program On June 1, 2018, the Board of Directors authorized up to $400 million for future repurchases of outstanding shares of Perspecta’s common stock. Repurchases may be made at the Company’s discretion from time to time on the open market depending on market conditions. The repurchase program has no time limit, does not obligate the Company to make any repurchases and may be suspended for periods or discontinued at any time. During the three and nine months ended December 31, 2018, the Company repurchased 967,240 shares and 1,890,428 shares of its common stock for aggregate cost of $21 million and $44 million, respectively, of which less than $1 million was settled subsequent to the end of the third quarter. The shares are reported as treasury stock at cost. The shares repurchased are retired immediately and included in the category of authorized but unissued shares. The total remaining authorization for future common share repurchases under the share repurchase program was $356 million as of December 31, 2018. Stock-based Compensation The Company recognized $4 million and $7 million in stock-based compensation expense during the three and nine months ended December 31, 2018, respectively. During the nine months ended December 31, 2018, the Company granted approximately 939,000 RSUs and approximately 521,000 performance-vested restricted stock units (“PSUs”). The RSUs granted included approximately 140,000 granted to key executives in connection with the Spin-Off and Mergers and approximately 63,000 granted to the Board of Directors according to Perspecta Board of Directors’ annual compensation plan. The RSUs and PSUs are valued using the closing price on the trading day of the grant. The weighted average grant date fair value of the RSUs and PSUs granted during the nine months ended December 31, 2018 was $24.40.

Stockholders' Equity

Description of Capital Stock

The Company has authorized share capital consisting of 750 million shares of common stock, par value $0.01 per share, and 1 million shares of preferred stock, par value $0.01 per share.

Each share of common stock is equal in all respects to every other share of common stock of the Company. Each share of common stock is entitled to one vote per share at each annual or special meeting of stockholders for the election of directors and upon any other matter coming before such meeting. Subject to all the rights of the preferred stock, dividends may be paid to holders of common stock as and when declared by the Board of Directors.

Cash Dividends

During the nine months ended December 31, 2018, the Board of Directors declared cash dividends to our stockholders of approximately $25 million in the aggregate, of which $17 million had been paid as of December 31, 2018 and $8 million of which was paid on January 15, 2019.

On February 13, 2019, the Board of Directors declared a dividend of $0.05 per share payable on April 16, 2019 to common stockholders of record at the close of business on March 27, 2019.

Share Repurchase Program

On June 1, 2018, the Board of Directors authorized up to $400 million for future repurchases of outstanding shares of Perspecta’s common stock. Repurchases may be made at the Company’s discretion from time to time on the open market depending on market conditions. The repurchase program has no time limit, does not obligate the Company to make any repurchases and may be suspended for periods or discontinued at any time. During the three and nine months ended December 31, 2018, the Company repurchased 967,240 shares and 1,890,428 shares of its common stock for aggregate cost of $21 million and $44 million, respectively, of which less than $1 million was settled subsequent to the end of the third quarter. The shares are reported as treasury stock at cost. The shares repurchased are retired immediately and included in the category of authorized but unissued shares. The total remaining authorization for future common share repurchases under the share repurchase program was $356 million as of December 31, 2018.

Stock-based Compensation

The Company recognized $4 million and $7 million in stock-based compensation expense during the three and nine months ended December 31, 2018, respectively. During the nine months ended December 31, 2018, the Company granted approximately 939,000 RSUs and approximately 521,000 performance-vested restricted stock units (“PSUs”). The RSUs granted included approximately 140,000 granted to key executives in connection with the Spin-Off and Mergers and approximately 63,000 granted to the Board of Directors according to Perspecta Board of Directors’ annual compensation plan. The RSUs and PSUs are valued using the closing price on the trading day of the grant. The weighted average grant date fair value of the RSUs and PSUs granted during the nine months ended December 31, 2018 was $24.40.